{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Fluhrer H"],"funding":["H2020 Marie Skłodowska-Curie Actions"],"pagination":["17588359221134065"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9679616"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14"],"pubmed_abstract":["Background
The treatment landscape of metastatic renal cell carcinoma (mRCC) has substantially advanced over the last three decades, whereby data from controlled clinical trials indicate significant improvements regarding patients' overall survival (OS) in highly selected patient cohorts. The aim of this study is to evaluate the impact of potentially game changing drugs on patients' outcomes by comparing three different historical mRCC treatment eras.Methods
In all, 914 mRCC patients who were diagnosed between July 1985 and September 2020 were included into this observational study and assigned to three different treatment eras ['cytokine', 'first-generation tyrosine kinase inhibitors (TKIs)', and 'modern TKIs/immunotherapy'] based on the EMA approval dates of sunitinib (Ju"],"journal":["Therapeutic advances in medical oncology"],"pubmed_title":["Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up."],"pmcid":["PMC9679616"],"funding_grant_id":["No 824036"],"pubmed_authors":["Bauernhofer T","Pichler M","Pichler R","Spiegelberg J","Ahyai S","Fluhrer H","Barth DA","Stidl M","Zigeuner R","Mischinger J","Jost PJ","Golbeck S","Seles M","Mannweiler S","Hutterer GC","Niedrist T"],"additional_accession":[]},"is_claimable":false,"name":"Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up.","description":"Background
The treatment landscape of metastatic renal cell carcinoma (mRCC) has substantially advanced over the last three decades, whereby data from controlled clinical trials indicate significant improvements regarding patients' overall survival (OS) in highly selected patient cohorts. The aim of this study is to evaluate the impact of potentially game changing drugs on patients' outcomes by comparing three different historical mRCC treatment eras.Methods
In all, 914 mRCC patients who were diagnosed between July 1985 and September 2020 were included into this observational study and assigned to three different treatment eras ['cytokine', 'first-generation tyrosine kinase inhibitors (TKIs)', and 'modern TKIs/immunotherapy'] based on the EMA approval dates of sunitinib (Ju","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-18T16:56:32.895Z","creation":"2025-04-07T04:26:54.556Z"},"accession":"S-EPMC9679616","cross_references":{"pubmed":["36425872"],"doi":["10.1177/17588359221134065"]}}